Tag Archives: obesity and diabetes

For decades, body mass index (BMI) has been the standard tool for assessing metabolic health and diabetes risk. However, many clinicians now question whether weight alone tells the full story. Some people with a “normal” BMI still develop insulin resistance and type 2 diabetes, while others with higher body weight …

Managing Type 2 diabetes used to follow a relatively predictable path. Clinicians often started with metformin and added medications gradually as glucose control worsened. Today, however, diabetes care looks very different. The number of available therapies has expanded rapidly, and while that growth has improved patient outcomes, it has also …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …

Why do some patients see impressive results with GLP-1 therapies while others barely respond? This question is becoming more relevant as clinicians encounter variability in outcomes. GLP-1 resistance is emerging as a possible explanation for suboptimal responses in certain individuals with diabetes. As a result, understanding how to identify and …

Can a therapy improve metabolic health even if the scale does not budge? This question is becoming increasingly relevant as clinicians observe patients benefiting from GLP-1 therapy even without significant weight loss. While weight reduction has long been a primary goal of incretin-based therapies, emerging data suggest that metabolic improvements …

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …